ストックスクリーナーアプリを入手
8.21
6.76%
0.52
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.29 - MarketBeat
Dominic Piscitelli Sells 8,851 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Pratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in Stock - MarketBeat
Oric Pharmaceuticals chief medical officer sells $73,293 in stock - Investing.com India
Oric Pharmaceuticals chief medical officer sells $73,293 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CFO sells $73,297 in stock - Investing.com India
Oric Pharmaceuticals CFO sells $73,297 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock - Investing.com
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock By Investing.com - Investing.com UK
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownTime to Sell? - MarketBeat
(ORIC) Technical Data - Stock Traders Daily
Charles Schwab Investment Management Inc. Boosts Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) Operating Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Fmr LLC Decreases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Position Lowered by Fmr LLC - MarketBeat
How to Take Advantage of moves in (ORIC) - Stock Traders Daily
ArrowMark Colorado Holdings LLC Acquires 80,986 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Fred Alger Management LLC Acquires 63,535 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Victory Capital Management Inc. Has $1.02 Million Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Consensus Price Target from Brokerages - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Major Healthcare Conferences in December | ORIC Stock News - StockTitan
Long Term Trading Analysis for (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (STU:4TZ) GF Value Rank : 0 (As of Nov. 22, 2024) - GuruFocus.com
ORIC Pharmaceuticals (STU:4TZ) Enterprise Value : €327.63 Mil (As of Nov. 21, 2024) - GuruFocus.com
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Research Analysts Issue Forecasts for ORIC FY2024 Earnings - Defense World
Oric Pharmaceuticals Inc (ORIC-Q) QuotePress Release - The Globe and Mail
Wedbush Lowers Earnings Estimates for ORIC Pharmaceuticals - Defense World
(ORIC) Trading Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks
Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com
Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com
ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World
Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology
ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia
ORIC-114 shows promise in preclinical cancer study - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):